InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,266.90
(
0.28%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: biomaven0 post# 9619

Monday, 06/20/2011 6:40:14 PM

Monday, June 20, 2011 6:40:14 PM

Post# of 80490
Peter, given that Gleevec has shown little benefit for high risk pts (Nature 2005), I think your view that this patient population represents the best opportunity to move ponatnib to 1st line is right on the mark. Using Sokal criteria, this could represent anywhere from 10% to 18% of newly diagnosed CML pts in the US and up to 30% of pts internationally. (see "Risk Stratification of Patients of Chronic Myeloid Leukemia According to Sokal Criteria")

btw, do you know of any trials that have been run comparing tasigna or sprycel to gleevec in high risk pts?
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up